Abstract
Purpose: Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials. We, retrospectively, analyzed the safety and efficacy of XELOX regimen in the treatment of elderly patients affected by mCRC.
Patients and methods: One-hundred-eleven consecutive patients, aged 70 years or older, were enrolled in the study.
Results: All patients were evaluated for safety and efficacy (male/female, 63/48). Median age was 75 years (range 71-85 years). Median Eastern Cooperative Oncology Group Performance Status (ECOG PS) was 0 (range 0-2). Metastatic sites distribution is as follows: liver (44.1%), lung (13.5%), liver plus lung (12.6%) and other (29.7%). A total of 584 cycles were administered (median 6 cycles/patient, range 2-10). Median follow-up time was 14.5 months (range 1-41 months). In an intent-to-treat analysis, objective responses and stable disease were recorded in 41 (40.4%) and 29 (26.6%) patients, respectively. The median response duration was 5.9 months (range 0.5-28.8). The median progression free-survival (PFS) was 7.5 months (range 1-26 months). The median overall survival (OS) was 15 months (range 1-64 months). The grade 3 toxicities were: neutropenia (8.1%), diarrhea and neurotoxicity (5.4% respectively). Most adverse events were mild to moderate; the most common was acute sensory neuropathy (57.6%).
Conclusion: XELOX is a highly effective first-line treatment for mCRC elderly patients. Response rates, PFS and OS are similar to those observed with fluorouracil/leucovorin/oxaliplatin combinations. XELOX is a convenient regimen, likely to be preferred by both patient and healthcare providers.
Keywords: Colorectal cancer, chemotherapy, oxaliplatin, elderly patients.
Anti-Cancer Agents in Medicinal Chemistry
Title:Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients
Volume: 13 Issue: 9
Author(s): Massimiliano Berretta, Giuseppe Aprile, Guglielmo Nasti, Martina Urbani, Alessandra Bearz, Stefania Lutrino, Luisa Foltran, Laura Ferrari, Renato Talamini, Francesco Fiorica, Arben Lleshi, Vincenzo Canzonieri, Chiara Lestuzzi, Eugenio Borsatti, Rossella Fisichella and Umberto Tirelli
Affiliation:
Keywords: Colorectal cancer, chemotherapy, oxaliplatin, elderly patients.
Abstract: Purpose: Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials. We, retrospectively, analyzed the safety and efficacy of XELOX regimen in the treatment of elderly patients affected by mCRC.
Patients and methods: One-hundred-eleven consecutive patients, aged 70 years or older, were enrolled in the study.
Results: All patients were evaluated for safety and efficacy (male/female, 63/48). Median age was 75 years (range 71-85 years). Median Eastern Cooperative Oncology Group Performance Status (ECOG PS) was 0 (range 0-2). Metastatic sites distribution is as follows: liver (44.1%), lung (13.5%), liver plus lung (12.6%) and other (29.7%). A total of 584 cycles were administered (median 6 cycles/patient, range 2-10). Median follow-up time was 14.5 months (range 1-41 months). In an intent-to-treat analysis, objective responses and stable disease were recorded in 41 (40.4%) and 29 (26.6%) patients, respectively. The median response duration was 5.9 months (range 0.5-28.8). The median progression free-survival (PFS) was 7.5 months (range 1-26 months). The median overall survival (OS) was 15 months (range 1-64 months). The grade 3 toxicities were: neutropenia (8.1%), diarrhea and neurotoxicity (5.4% respectively). Most adverse events were mild to moderate; the most common was acute sensory neuropathy (57.6%).
Conclusion: XELOX is a highly effective first-line treatment for mCRC elderly patients. Response rates, PFS and OS are similar to those observed with fluorouracil/leucovorin/oxaliplatin combinations. XELOX is a convenient regimen, likely to be preferred by both patient and healthcare providers.
Export Options
About this article
Cite this article as:
Berretta Massimiliano, Aprile Giuseppe, Nasti Guglielmo, Urbani Martina, Bearz Alessandra, Lutrino Stefania, Foltran Luisa, Ferrari Laura, Talamini Renato, Fiorica Francesco, Lleshi Arben, Canzonieri Vincenzo, Lestuzzi Chiara, Borsatti Eugenio, Fisichella Rossella and Tirelli Umberto, Oxaliplapin and Capecitabine (XELOX) Based Chemotherapy in the Treatment of Metastatic Colorectal Cancer: The Right Choice in Elderly Patients, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660347
DOI https://dx.doi.org/10.2174/18715206113136660347 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Wnt Signaling in Development, Disease and Translational Medicine
Current Drug Targets Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)
Current Pharmaceutical Design Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
Current Cancer Drug Targets Design, Synthesis and Biological Evaluation of a Novel Series of Indole-3- Carboxamide Derivatives for Cancer Treatment as EGFR Inhibitors
Letters in Drug Design & Discovery Transcriptional Control of Collagen I Gene Expression
Cardiovascular & Hematological Disorders-Drug Targets How is Gene Transfection Able to Improve Current Chemotherapy? The Role of Combined Therapy in Cancer Treatment
Current Medicinal Chemistry microRNAs: Innovative Targets for Cerebral Ischemia and Stroke
Current Drug Targets Markov-Randic Indices for QSPR Re-Evaluation of Metabolic, Parasite- Host, Fasciolosis Spreading, Brain Cortex and Legal-Social Complex Networks
Current Bioinformatics Red Blood Cells as Modulators of T Cell Growth and Survival
Current Pharmaceutical Design Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family
Current Drug Targets Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems
Current Pharmaceutical Design Do We Have Another Option to Treat Bleeding Hemorrhoids? The Emborrhoid Technique: Experience in 16 Patients
Reviews on Recent Clinical Trials Chemoprevention with Phytonutrients and Microalgae Products in Chronic Inflammation and Colon Cancer
Current Pharmaceutical Design